Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Eli Lilly and Company recently completed a Phase 1 clinical study titled ‘A Phase 1, Open-Label, Multiple-Dose Study to Investigate the Comparability of the Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants.’ The study aimed to evaluate how the body absorbs and processes Orforglipron when administered as a single capsule versus multiple capsules under both fasted and fed conditions. Additionally, the study assessed the safety and tolerability of the drug.
The intervention tested was Orforglipron, an experimental drug administered orally. The study focused on understanding the pharmacokinetics of different dosing forms to optimize its delivery and efficacy.
This interventional study followed a randomized, crossover design with no masking, primarily for basic science purposes. Participants received different sequences of Orforglipron doses to compare pharmacokinetic profiles.
The study began on December 13, 2024, and was last updated on June 23, 2025. These dates are crucial as they mark the study’s progression and the availability of updated information for stakeholders.
The completion of this study may influence Eli Lilly’s stock performance positively, as successful results could enhance investor confidence in Orforglipron’s potential. In the competitive pharmaceutical landscape, advancements in drug delivery methods can offer a significant edge.
The study is completed, and further details can be accessed on the ClinicalTrials portal.